The role of inflammation in diabetic cardiomyopathy

International Journal of Interferon, Cytokine and Mediator Research

Volumn 4, Issue 1, 2012, Pages 59-73

  Nunes, Sara ^a   Soares, Edna ^a   Pereira, Frederico ^a   Reis, Flávio ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Inflammation; Inflammatory process; Myocardium; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ATORVASTATIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; IRBESARTAN; LIRAGLUTIDE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SITAGLIPTIN; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETOGENESIS; DIASTOLIC DYSFUNCTION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MEGADOSE; EXERCISE; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOTOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PUBLIC HEALTH PROBLEM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION;

EID: 84864849181     PISSN: None     EISSN: 1179139X     Source Type: Journal    
DOI: 10.2147/IJICMR.S21679     Document Type: Review

References (158)

1. George B, Cebioglu M, Yeghiazaryan K. Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J. 2010;1(1):13-18.
2. Copeland KC, Becker D, Gottschalk M, Hale D. Type 2 diabetes in children and adolescents: risk factors, diagnosis, and treatment. Clinical Diabetes. 2005;23(4):181-185.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(27):1047-1053.
4. International Diabetes Federation (IDF). IDF Diabetes Atlas. 4th ed. Brussels: IDF; 2010.
5. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77-82.
6. Tuomilehto J, Lindström J. The major diabetes prevention trials. Curr Diab Rep. 2003;3(2):115-122.
7. Fisher M. Diabetes: can we stop the time bomb? Heart. 2003;89 Suppl 2:ii28-ii30; discussion ii35-ii37.
8. Bäcklund T, Palojoki E, Saraste A, et al. Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia. 2004;47(2):325-330.
9. Yang ZH, Peng XD. Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus. Acta Cardiol. 2010;65(3):329-335.
10. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29-34.
11. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996; 77(11):1017-1020.
12. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595-602.
13. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68(1):85-89.
14. Shrestha NR, Sharma SK, Karki P, Shrestha NK, Acharya P. Echocardiographic evaluation of diastolic function in asymptomatic type 2 diabetes. J Nepal Med Assoc. 2009;48(173):20-23.
15. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4): 543-567.
16. Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis. 2005;16 Suppl 1:S3-S10.
17. Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003;41(4):611-617.
18. Karamitsos TD, Karvounis HI, Dalamanga EG, etal. Early diastolic impairment of diabetic heart: the significance of right ventricle. Int J Cardiol. 2007;114(2):218-223.
19. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002;98(1-2):33-39.
20. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol. 2007;42(4):884-895.
21. Loganathan R, Bilgen M, Al-Hafez B, Alenezy MD, Smirnova IV. Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging. Cardiovasc Diabetol. 2006;5:7.
22. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4mice. Am J Physiol Heart Circ Physiol. 2002;283(3):H976-H982.
23. Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M. LV function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol. 1992;70(3):371-378.
24. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93(7):870-875.
25. Celentano A, Vaccaro O, Tammaro P, etal. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol. 1995;76(16):1173-1176.
26. Andersen NH, Poulsen SH, Helleberg K, Ivarsen P, Knudsen ST, Mogensen CE. Impact of essential hypertension and diabetes mellitus on left ventricular systolic and diastolic performance. Eur J Echocardiogr. 2003;4(4):306-312.
27. Ballo P, Cameli M, Mondillo S, et al. Impact of diabetes and hypertension on left ventricular longitudinal systolic function. Diabetes Res Clin Pract. 2010;90(2):209-215.
28. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci. 2001;69(5):527-542.
29. Mytas DZ, Stougiannos PN, Zairis MN, Foussas SG, Pyrgakis VN, Kyriazis IA. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications. 2009; 23(4):273-282.
30. Radovits T, Korkmaz S, Loganathan S, etal. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2009;297(1):H125-H133.
31. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010; 16(12):971-979.
32. Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49(5):962-970.
33. Devereux RB, Roman MJ, Parancias M, etal. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101(19):2271-2276.
34. Karason K, Sjöström L, Wallentin I, Peltonen M. Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J. 2003;24(16):1500-1505.
35. Holmäng A, Yoshida N, Jennische E, Waldenström A, Björntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest. 1996;26(11): 973-978.
36. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003;108(6):754-759.
37. van Heerebeek L, Hamdani N, Handoko ML, etal. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51.
38. Mizushige K, Yao L, Noma T, etal. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101(8):899-907.
39. Tschöpe C, Walther T, Königer J, etal. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 2004;18(7):828-835.
40. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582-592.
41. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21(1):3-12.
42. Brüning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2in IRS-1-deficient cells. Mol Cell Biol. 1997;17(3):1513-1521.
43. Zecchin HG, Carvalheira JB, Saad MJ. Mecanismos moleculares de resistência à insulina na síndrome metabólica [Molecular mechanisms of insulin resistance in metabolic syndrome]. Rev Soc Cardiol Estado de São Paulo. 2004;14(4):574-589. Portuguese.
44. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28(5):463-491.
45. Perseghin J, Petersen K, Shulman G. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S6-S11.
46. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 1998;180(1-2):53-57.
47. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339-342.
48. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol. 2010;88(3):233-240.
49. Eckel J, Reinauer H. Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans. 1990;18(6):1125-1127.
50. Finck BN, Han X, Courtois M, etal. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003; 100(3):1226-1231.
51. Son NH, Park TS, Yamashita H, etal. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007; 117(10):2791-2801.
52. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000; 87(3):179-183.
53. Candido R, Forbes JM, Thomas MC, etal. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785-792.
54. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets. 2007; 8(10):1138-1143.
55. Yan SF, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med. 2007;7(8):699-710.
56. Bidasee KR, Nallani K, Yu Y, etal. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes. 2003;52(7):1825-1836.
57. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6):859-866.
58. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55(6): 498-510.
59. Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol. 2009;8:8.
60. Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011;89(3):516-524.
61. Guzik TJ, Mussa S, Gastaldi D, etal. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105(14):1656-1662.
62. Niklason A, Hedner T, Niskanen L, Lanke J; Captopril Prevention Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients-a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004;22(3):645-652.
63. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav. 2010;100(5):525-534.
64. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821-826.
65. Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol. 2010;8(2):189-197.
66. McGuire DK, Winterfield JR, Rytlewski JA, Ferrannini E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res. 2008;5(1):59-66.
67. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003;42(2):206-212.
68. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-236.
69. Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol. 1999;277(5 Pt 1):E920-E926.
70. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57(12):3297-3306.
71. Lee JH, Xia S, Ragolia L. Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(1):R144-R154.
72. Siddiqui AH, Hussain T. Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol. 2007;292(4):H1722-H1727.
73. Fiordaliso F, Li B, Latini R, etal. Mycocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest. 2000;80(4):513-527.
74. Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl. 1997;15(6):S13-S19.
75. Dostal DE, Booz GW, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol. 2000;95(6):485-490.
76. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramírez E, Egido J, Tuñón J. Potential role of nuclear factor κB in diabetic cardiomyopathy. Mediators Inflamm. 2011:652097.
77. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud. 2004;1(4):165-174.
78. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;148(7): 3356-3363.
79. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148(1):241-251.
80. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl). 2003;81(8):455-470.
81. Yu XY, Chen HM, Liang JL, etal. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS One. 2011;6(1):e16239.
82. Mano Y, Anzai T, Kaneko H, etal. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J. 2011;75(7):1717-1727.
83. Westermann D, Rutschow S, Van Linthout S, etal. Inhibition of p38mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006;49(10):2507-2513.
84. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman ML, Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5): 1247-1252.
85. Sun M, Dawood F, Wen WH, etal. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110(20):3221-3228.
86. Younce CW, Wang K, Kolattukudy PE. Hyperglycemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovas Res. 2010;87: 665-674.
87. Ares-Carrasco S, Picatoste B, Benito-Martín A, etal. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Am J Physiol Heart Circ Physiol. 2009;297(6):H2109-H2119.
88. Ares-Carrasco S, Picatoste B, Camafeita E, etal. Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARα in the associated hypertrophy. J Proteomics. 2012;75(6): 1816-1829.
89. Kawaguchi M, Techigawara M, Ishihata T, etal. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels. 1997;12(6):267-274.
90. Westermann D, Rutschow S, Jäger S, etal. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007;56(3):641-646.
91. Kaneko K, Kanda T, Yokoyama T, etal. Expression of interleukin-6in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol. 1997;97(1):3-12.
92. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87(12): 1195-1201.
93. Hernández-Presa M, Bustos C, Ortego M, etal. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κ B activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95(6):1532-1541.
94. Hopps E, Canino B, Caimi G. Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol. 2011;48(3):183-189.
95. de Lemos ET, Reis F, Baptista S, etal. Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type 2) diabetic rats. Med Sci Monit. 2007;13(8):BR168-BR174.
96. Teixeira de Lemos E, Reis F, Baptista S, etal. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition. 2009;25(3):330-339.
97. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol. 2011;10:12.
98. Teixeira de Lemos E, Pinto R, Oliveira J, etal. Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus. Mediators Inflamm. 2011;2011:253061.
99. Ziccardi P, Nappo F, Giugliano G, etal. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7): 804-809.
100. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105(5):564-569.
101. Mao XM, Liu H, Tao XJ, Yin GP, Li Q, Wang SK. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2009;25(5):435-441.
102. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009; 53(Suppl 5):S14-S20.
103. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-865.
104. Gundewar S, Calvert JW, Jha S, etal. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104(3):403-411.
105. Xie Z, Lau K, Eby B, etal. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26mice. Diabetes. 2011;60(6):1770-1778.
106. Caballero AE, Delgado A, Aguilar-Salinas CA, etal. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled randomized clinical trial. J Clin Endocrinol Metab. 2004; 89(8):3943-3948.
107. Kim SK, Zhao ZS, Lee YJ, etal. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or-gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev. 2003;19(6):487-493.
108. Tsuji T, Mizushige K, Noma T, etal. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol. 2001;38(6):868-874.
109. Bibra HV, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diabetes Vasc Dis Res. 2008;5(4):310-318.
110. Terui G, Goto T, Katsuta M, Aoki I, Ito H. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol. 2009;54(1):52-58.
111. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104(14): 1670-1675.
112. Dargie HJ, Hildebrandt PR, Riegger GA, etal. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol. 2007;49(16):1696-1704.
113. Naka KK, Pappas K, Papathanassiou K, etal. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc Diabetol. 2010;9:57.
114. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond). 2004; 107(6):539-557.
115. Takano H, Nagai T, Asakawa M, etal. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 2000;87(7):596-602.
116. Nesto RW, Bell D, Bonow RO, etal; American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation. October 7, 2003;108(23):2941-2948.
117. Cheng AY, Fantus IG. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother. 2004;38(5):817-820.
118. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116(3): 615-622.
119. Leroy C, Tricot S, Lacour B, Grynberg A. Protective effect of eicosapentaenoic acid on palmitate-induced apoptosis in neonatal cardiomyocytes. Biochim Biophys Acta. 2008;1781(11-12):685-693.
120. Bishopric NH, Andreka P, Slepak T, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol. 2001;1(2):141-150.
121. Lee SD, Kuo WW, Lin JA, etal. Effects of long-term intermittent hypoxia on mitochondrial and Fas death receptor dependent apoptotic pathways in rat hearts. Int J Cardiol. 2007;116(3):348-356.
122. Baraka A, Abdel Gawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther. 2010;15(2):175-181.
123. Pérez-Pérez R, Ortega-Delgado FJ, García-Santos E, etal. Differential proteomics of omental and subcutaneous adipose tissue reflects their unalike biochemical and metabolic properties. J Proteome Res. 2009; 8(4):1682-1693.
124. Anagnostis P, Athyros VG, Adamidou F, etal. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302-312.
125. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2011;11:6.
126. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983.
127. Saraceni C, Broderick TL. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D. 2007;8(3):45-53.
128. Ravassa S, Zudaire A, Díez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94(2):316-323.
129. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007;21(4):253-256.
130. Ossum A, van Deurs U, Engstrøm T, Jensen JS, Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1 (9-36) a in an isolated rat heart. Pharmacol Res. 2009;60(5):411-417.
131. Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept. 2005;128(2):125-134.
132. Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011;17(38):4379-4385.
133. Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37(6):477-488.
134. Hattori Y, Jojima T, Tomizawa A, etal. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256-2263.
135. Mells JE, Fu PP, Sharma S, etal. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol. 2012;302(2): G225-G235.
136. Gomez N, Touihri K, Matheeussen V, etal. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14-21.
137. Chaykovska L, von Websky K, Rahnenführer J, etal. Effects of DPP-4inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861.
138. Ferreira L, Teixeira-de-Lemos E, Pinto F, etal. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010; 2010:Article ID 592760.
139. Mega C, Teixeira de Lemos E, Vala H, etal. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res. 2011;2011: Article ID 162092.
140. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
141. Takemoto M, Node K, Nakagami H, etal. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429-1437.
142. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-III43.
143. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63(1):12-23.
144. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332-337.
145. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8(17):3061-3068.
146. Van Linthout S, Riad A, Dhayat N, etal. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia. 2007;50(9):1977-1986.
147. Ye P, Sheng L, Zhang C, Liu Y. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci. 2006;9(3):365-375.
148. Shekelle PG, Rich MW, Morton SC, etal. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529-1538.
149. Zaman AK, Fujii S, Goto D, etal. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol. 2004;37(2):525-535.
150. Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, etal. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin. 2007;59(2):103-107.
151. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004;64(22):2537-2565.
152. Di Filippo C, Lampa E, Tufariello E, etal. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res. 2005;13(11):1909-1914.
153. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1): 20-27.
154. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-1107.
155. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003;305:846-853.
156. Nerry Serneri GG, Boddi M, Modesti PA, etal. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res. 2004;94(12):1630-1637.
157. Gullestad L, Aukrust P, Ueland T, etal. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34(7):2061-2067.
158. Tsutamoto T, Wada A, Maeda K, etal. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35(3):714-721.